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The deconstruction of vulnerability to complex disease with the help of intermediate 
phenotypes, including the heritable and disease-associated endophenotypes, is a legacy 
of Henri Begleiter. Systematic searches for genes influencing complex disorders, 
including bipolar disorder, have recently been completed using whole genome 
association (WGA), identifying a series of validated loci. Using this information, it is 
possible to compare effect sizes of disease loci discovered in very large samples to the 
effect sizes of replicated functional loci determining intermediate phenotypes that are of 
essential interest in psychiatric disorders. It is shown that the genes influencing 
intermediate phenotypes tend to have a larger effect size. Furthermore, the WGA results 
reveal that the number of loci of large effect size for complex diseases is limited, and yet 
multiple functional loci have already been identified for intermediate phenotypes relevant 
to psychiatric diseases, and without the benefit of WGA.  
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Begleiter et al.[1] reported that amplitude of the P300 event-related potential was reduced in the alcohol-
naïve, genetically at-risk, male offspring of alcoholics. This discovery indicated a disturbance of 
attentional processes in these boys and innate vulnerability due to impaired executive cognitive processes. 
Because alcoholism vulnerability is mediated by diverse mechanisms, identification of the P300 trait 
represented a key first step in a functionally based deconstruction of the illness of alcoholism and towards 
a more etiologically based redefinition of the disease. Subsequently, the low-amplitude P300 trait was 
also shown to be moderately heritable, thus establishing it as an endophenotype according to the 
definition of Gottesman and Gould[2].  
Intermediate phenotypes can be defined as mechanism-related manifestations of complex phenotypes. 
Intermediate phenotypes that are heritable are called endophenotypes (see Fig. 1). Not all intermediate 
phenotypes useful in genetic studies are both heritable and disease associated, and some are neither[3]. 
For example, the intermediate phenotype of flushing is protective against alcoholism; rather than being 
more common in the disease, it is actually less common. Less obviously, but very frequently, intermediate 
phenotypes identify distinct subsets, sometimes very small, of the whole population of patients with a  




FIGURE 1. Definition of phenotype, intermediate phenotype, and endophenotype. 
complex disease. In these instances, the intermediate phenotype is recognized to be disease associated 
only in retrospect, and after the intermediate phenotype has been used to redefine the disease. For 
example alcoholism, with a heritability of >0.50 and perhaps as high as 0.65[4], exhibits a higher 
heritability than P300 amplitude, which has a heritability of approximately 0.40[5]. However, the P300 
trait identifies a more homogeneous population of alcoholics sharing a mechanism of vulnerability. 
Intermediate phenotypes also direct attention to particular genes and other etiologic factors, and enable 
directional predictions with functional alleles or these other etiologic factors. A noncomprehensive list of 
intermediate phenotypes for alcoholism is provided in Table 1. For several of these intermediate 
phenotypes, the involvement of particular genes was predicted on the basis of function and, in several 
instances, a functional locus has been replicably linked, as indicated.  
The purpose of this paper is to compare the effect sizes of genes in complex diseases vs. those that 
have been discovered to influence intermediate phenotypes such as those listed. We would also like to 
begin to address the question of what fraction of the genes for complex diseases are discoverable using 
disease diagnosis alone. It is necessary to first observe that comprehensive lists of gene effects are 
available for neither. However, the recent completion of the Wellcome Trust WGA[6] study for seven 
complex diseases enables us to know with confidence all of the loci that are, on a genome-wide basis, 
capable of generating a significant signal in a comparison of 2,000 cases to 3,000 controls, and with a 
relatively dense (550,000 single nucleotide polymorphisms) genetic map. As shown in Table 2, the range 
of loci detected at the genome-wide confidence level ranged from a low of one for bipolar disorder to a 
high of seven for Crohn’s disease. This study succeeded in detecting all previously replicated loci, so it is 
highly likely that few, if any, further loci of large effect will be discovered for any of them. The 
maximum genotype-specific effect sizes for these disease loci range from 1.5 to 18.5, with a median of 
1.9. The fact that no locus with an effect size of less than 1.5 was detected even in this series of very large 
(2,000/3,000) case/control studies has very important implications, but here we are not concerned with the 
technical issue of power, but rather with the genetic architecture of the disease diagnosis, something that 
will not change even if sample size and marker density are increased. Even with these technical 
improvements, it is likely that additional loci detected will be of smaller effect, and extraordinarily large 
samples are required for loci of small effect.  




Intermediate Phenotypes for Alcoholism 
Domain How Assessed Heritability* Locus 
Diagnosis (e.g., dependence) Diagnostic interview (e.g., 
SSAGA, SCID) 
High  
Attention/dyscontrol Low amplitude P300 
Frontal cognitive tasks 
Task-specific MRI 
Questionnaires  
Moderate COMT Val158Met (rs4680) 
MAOA-LPR 
Pharmacokinetics Flushing questionnaires 
Metabolite levels 
High ALDH2 Glu487Lys (rs671) 
ADH1B His47Arg (rs1229984) 
Level of response Alcohol challenge/clamp 
Questionnaire (i.e., SRE) 
High  
Treatment response Response in clinical trials ? OPRM1 Asn40Asp (rs1799971) 
Resting EEG  α, β resting EEG power High  
Mesolimbic reward Task-related MRI, PET ?  
Stress/resiliency Task-related MRI, PET 
Endocrine responses 
Questionnaires 
? HTTLPR (La, S, Lg) 
COMT Val158Met (rs4680) 
NPY 
Brain volume/structure MRI structure Region 
dependent 
BDNF Met66Val (rs6265) 
MAOA-LPR 
HTTLPR 
COMT Val158Met (rs4680) 
* High: >50%; Moderate: 30–40%.  
The disease loci listed and detected by WGA represent important clues to etiology, but account for 
only a small portion of the total genetic variance in these diseases. For example, bipolar disorder has a 
heritability of 80–90% and a seven- to tenfold elevated recurrence risk in first-degree relatives of 
probands. The 16p12 locus listed is found in approximately one-half of bipolar cases and with an odds 
effect of approximately 2.1, accounts for perhaps 4% of the genetic risk for bipolar disorder. This leads to 
the conclusion that case/control samples for WGA need to be enlarged even further, but with rapidly 
diminishing returns, or that alternative strategies should be employed to better target genetic studies, as 
done before with candidate gene studies and studies on particular families, or to increase the effect size, 
as now will be discussed. 
In contrast to the complex disease approach, the intermediate phenotype approach attempts to home in 
on mechanisms of vulnerability. For example, the activation of the brain stress axis constitutes a so-called 
“dark side” response to reinforcing drugs, leading to long-lasting and even lifelong vulnerability to stress-
induced reinstatement of drug use, as well as cue-induced reinstatement. Functional loci at four genes, 
catechol-O-methyltransferase (COMT), the serotonin transporter (5-HTT), MAOA-LPR, and neuropeptide 
Y (NPY), have been linked to specific neural circuits associated with cognition and emotion. A functional 
missense variant in COMT, Val158Met (rs4680), partially accounts for variation in metabolic responses to 
working memory tasks in prefrontal cortex (PFC)[7], attentional control in cingulate cortex, and emotion in 
amygdala. The Met allele that leads to lower enzyme activity and predicts higher dopamine levels is 
associated with improved working memory and attentional control, but is also correlated with emotional 
response. Thus, the Met allele appears to be beneficial for cognitive function, at least under conditions of 
low or moderate stress, while the Val allele may benefit emotional resiliency. These results are consistent 
with higher pain/stress threshold and lower affective response to pain observed in Val carriers, and the 
greater ability of these individuals to activate brain opioid release after a pain/stress. In children, COMT 
genotypes strongly predict cognitive behavioral performance attributable to the prefrontal cortex, but not  




Effect Sizes of Loci for Seven Diseases Analyzed by WGA in the Wellcome Trust Study  
Phenotype Locus Heterozygote Odds Ratio Homozygote Odds Ratio 
Bipolar disease 16p12 2.1 2.1 
Coronary artery disease 9p21 1.5 1.9 
Crohn’s disease 1p31 1.4 1.9 
 2q37 1.2 1.9 
 3p21 1.1 1.8 
 5p13 1.5 2.3 
 5q33 1.5 1.9 
 10q21 1.2 1.6 
 10q24 1.2 1.6 
 16q12 1.3 1.9 
 18p11 1.3 2.0 
Rheumatoid arthritis (RA) 1p13 2.0 3.3 
 6 2.4 5.2 
Type 1 diabetes (T1D) 1p13 1.8 5.2 
 6 5.5 18.5 
 12q13 1.3 1.8 
 12q24 1.3 1.9 
 16p13 1.2 1.6 
Type 2 diabetes 6p22 1.2 2.2 
 10q25 1.4 1.9 
 16q12 1.3 1.6 
T1D, multilocus 4q27 1.3 1.5 
 12p13 1.6 1.5 
RA, sex differentiated 7q32 1.4 1.6 
RA + T1D 10p15 1.4 1.6 
performance attributable to the dorsolateral prefrontal cortex. The functional polymorphism of the 
promoter region of the serotonin transporter gene (HTTPLR) has also been related to emotional processes. 
The short allele (S) that reduces the serotonin transporter gene (SLC6A4) transcription is associated with 
decreased amygdala activation by neutral stimuli, but enhanced activation by aversive or ambiguous 
cues[8] (Fig. 2). The S allele effect appears partly mediated by a decrease in connectivity to frontal and 
cingulate cortices, which modulate amygdala activity, and to structural changes, suggesting the possibility 
of effects on developing neurocircuitry in children.  
The HTTLPR and COMT effects appear additive, presaging a future in which effects of various 
functional alleles are integrated with each other and with environmental predictors. A functional 
polymorphism (MAOA-LPR) located in the promoter region of monoamine oxidase A gene (MAOA) has 
been shown to moderate neuronal circuits associated with aggression and impulsivity. The low-activity 
variant at this locus predicted reduced limbic volume and hyper-reactivity of amygdala during emotional 
arousal, with diminished reactivity of regulatory prefrontal regions, compared with the high expression 
allele[9]. Consistently with these results, the low-activity variant has been reported to predict antisocial 
problems[10] and alcoholism[11]. 




FIGURE 2. Serotonin transporter promoter polymorphism (HTTLPR) and relationship with amygdala activation 
during negative emotional stimuli. (A) A bi-allelic HTTLPR and a tri-allelic HTTLPR. Two forms of bi-allelic 
HTTLPR: long allele (L) and short allele (S). S allele decreases 5-HTT transcription and is associated with lower 5-
HTT function. An additional A>G SNP is located on L allele of HTTLPR. LG decreases 5-HTT transcription similar 
to S allele. LA allele predicts greatest 5-HTT transcription and highest 5-HTT function. (B) Individuals with S allele 
increase amygdala activation, while individuals with LA allele have lowest activation in amygdala after negative 
emotional stimuli.  
Effect sizes for functional loci in several intermediate phenotypes, including those just discussed, are 
listed in Table 3. It should be noted that a systematic scan for genes for any of these intermediate 
phenotypes has not been performed. Furthermore, the intermediate phenotype linkages detected and 
replicated thus far are necessarily of large effect size because they have been detected in relatively small 
datasets that are not powered to detect small effects. Nevertheless, and as shown in the table, this is a 
strategy that generates additional phenotypes on which functional alleles exert large effects, and yields 
immediate information on the mechanism of action of the functional allele. Genotype-specific effect sizes 
(Odds Ratio [OR]) reported in Table 3 have been computed for each intermediate phenotype, comparing 
the percentages of subjects within each genotype group who belong to the top third of the phenotype 
distribution vs. the percentage who belong to the bottom third of the trait distribution. This approach fails 
to capture all the information inherent in the quantitative trait, the adequacy of the approach depending on 
the varying precision with which each intermediate phenotype is estimated. Obviously genotype-specific 
ORs are much higher if more extreme tails of the quantitative distribution are compared, however in that 
case, sample sizes are reduced or some special phenotype- or genotype-based procedure would be 
required to enhance collection of individuals who are at the extremes of the distribution. Maximum 
genotype-dependent ORs calculated in this very conservative fashion range between 1.7 and 6.0. Of note, 
the lowest OR is for harm avoidance, a phenotype that can be considered a more complex phenotype than 
task-specific brain activation measured with functional MRI. Considering only fMRI studies, the median 
OR is 3.5, which is approximately twice the median locus-specific OR reported for the complex diseases 
in the Wellcome Trust WGA study.  




Effect Sizes of Three Functional Loci on Different Intermediate Phenotypes for Psychiatric 
Diseases 





WCST Healthy controls 55 Val/Val vs. Met/Met 6.0 [7] 
     Val/Val vs. Val/Met 1.7  
   Schizophrenics 175 Val/Val vs. Met/Met 2.1  
     Val/Val vs. Val/Met 1.6  
5-HTTLPR Amygdala 
activation 
Healthy controls 92 ss vs. ll or ls 3.9 [8] 
5-HTTLPR Harm avoidance Mixed 5224 ss vs. ll 1.7 [12] 
     ss vs. sl 1.6  
MAOA-LPR Amygdala 
activation 
Healthy controls 77 Low vs. High 3.9 [9] 
  OCF activation Healthy controls 77 Low vs. High 3.1  
  Hippocampus 
activation 
Healthy controls 44 Low vs. High 2.6  
CONCLUSION 
The small effect sizes of genes in complex diseases and limited number of loci detectable in large 
case/control datasets analyzed so far may presage an ultimate limit to the ability of this approach to access 
the genetic architecture of complex disease even with ever larger datasets, without preceding 
deconstruction of the complex phenotype with the help of intermediate phenotypes. Replicated linkages 
of functional loci to intermediate phenotypes in relatively small datasets indicate that WGA studies 
conducted on intermediate phenotypes, such as fMRI, are a powerful method to discover new genes that 
moderate brain activity. The large genotype-specific effect sizes detected by the functional 
locus/intermediate phenotype approach helps to explain the successes achieved with this method.  
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